Evidence for the Benefits of Nonantipsychotic Pharmacological Augmentation in the Treatment of Depression
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, Chia-Ming | - |
dc.contributor.author | Sato, Soichiro | - |
dc.contributor.author | Han, Changsu | - |
dc.date.accessioned | 2021-09-06T11:30:20Z | - |
dc.date.available | 2021-09-06T11:30:20Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1172-7047 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/106518 | - |
dc.description.abstract | Failure to achieve an adequate response after initial antidepressant treatment in patients with depression is common and remains a clinical challenge. In recent years, some atypical antipsychotic agents have been approved by the US Food and Drug Administration for use in an augmentation strategy for major depressive disorder, and other agents are already in common use in clinical practice. We conducted a search of MEDLINE for relevant studies of augmentation strategies using randomized controlled trials and meta-analyses, and we summarize and discuss the various agents other than atypical antipsychotics. Lithium and thyroid hormone augmentation may improve the response of tricyclic antidepressants but not that of selective serotonin reuptake inhibitors. The efficacy of augmentation with modafinil, buspirone, methylphenidate, folic acid, pindolol and lamotrigine is limited or equivocal. Most of the studies have not focused on treatment-resistant depression (TRD). More trials are needed to help develop evidence-based options for augmentation in TRD. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ADIS INT LTD | - |
dc.subject | TREATMENT-RESISTANT-DEPRESSION | - |
dc.subject | PLACEBO-CONTROLLED TRIAL | - |
dc.subject | SEROTONIN REUPTAKE INHIBITORS | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | LITHIUM AUGMENTATION | - |
dc.subject | TRIIODOTHYRONINE AUGMENTATION | - |
dc.subject | TRICYCLIC ANTIDEPRESSANTS | - |
dc.subject | REFRACTORY DEPRESSION | - |
dc.subject | RESIDUAL SYMPTOMS | - |
dc.subject | CLINICAL-TRIALS | - |
dc.title | Evidence for the Benefits of Nonantipsychotic Pharmacological Augmentation in the Treatment of Depression | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.identifier.doi | 10.1007/s40263-012-0030-1 | - |
dc.identifier.scopusid | 2-s2.0-84886281128 | - |
dc.identifier.wosid | 000321464900004 | - |
dc.identifier.bibliographicCitation | CNS DRUGS, v.27, pp.S21 - S27 | - |
dc.relation.isPartOf | CNS DRUGS | - |
dc.citation.title | CNS DRUGS | - |
dc.citation.volume | 27 | - |
dc.citation.startPage | S21 | - |
dc.citation.endPage | S27 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | TREATMENT-RESISTANT-DEPRESSION | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | SEROTONIN REUPTAKE INHIBITORS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | LITHIUM AUGMENTATION | - |
dc.subject.keywordPlus | TRIIODOTHYRONINE AUGMENTATION | - |
dc.subject.keywordPlus | TRICYCLIC ANTIDEPRESSANTS | - |
dc.subject.keywordPlus | REFRACTORY DEPRESSION | - |
dc.subject.keywordPlus | RESIDUAL SYMPTOMS | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.